GlassScriptPhysician profile
Brandy Kay Holmes
NPI 1528849700
$1,622.25
in general payments reported to CMS, 2019-2025
13 companies · $732 in 2025
The $732 reported for 2025 was more than what 81% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $115 · 2024: $775 · 2025: $732.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,622.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,622.25 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biotronik Nro, INC. | $279.43 | 2024 | Prospera |
| Corcept Therapeutics | $227.29 | 2024 | Korlym |
| Inspire Medical Systems, INC. | $142.97 | 2025 | Inspire |
| Genzyme Corporation | $124.99 | 2025 | |
| Shionogi INC | $124.22 | 2025 | |
| Boston Scientific Corporation | $124.17 | 2025 | Watchman Flx |
| E.R. Squibb & Sons, L.L.C. | $123.07 | 2024 | Reblozyl |
| Kyowa Kirin, INC. | $115.36 | 2023 | |
| Sandoz INC. | $112.43 | 2025 | |
| Phathom Pharmaceuticals, INC. | $103.11 | 2025 | Voquezna |
| Astrazeneca Pharmaceuticals LP | $68.29 | 2024 | Airsupra |
| Acadia Pharmaceuticals INC | $42.16 | 2024 | Nuplazid |
| Sk Life Science, INC. | $34.76 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Brandy Holmes listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.